Degarelix 80mg Injection is a gonadotrophin-releasing hormone (GnRH) receptor antagonist used as androgen-deprivation therapy in adult men with hormone-dependent prostate cancer. In the UK, the electronic Medicines Compendium lists FIRMAGON 80mg and Degarelix Ferring 80mg powder and solvent for solution for injection.
Degarelix works by directly blocking GnRH receptors, reducing luteinising hormone (LH), follicle-stimulating hormone (FSH), and testosterone production. Unlike GnRH agonists, degarelix does not produce the initial testosterone surge associated with agonist therapy.
In the UK, degarelix is indicated for adult male patients with advanced hormone-dependent prostate cancer. The UK SmPC also includes use in high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy, and as neoadjuvant treatment before radiotherapy in specified patients.
Degarelix is therefore used as a form of androgen-deprivation therapy (ADT) where lowering testosterone is an important component of prostate cancer management.
Degarelix directly blocks the GnRH receptor in the pituitary gland. This suppresses LH and FSH secretion and consequently reduces testosterone production.
This mechanism differs from GnRH agonists because degarelix does not produce the initial LH-driven testosterone surge associated with agonist initiation. The UK SmPC describes rapid suppression of testosterone following treatment and sustained suppression during maintenance therapy.
Degarelix is the active pharmaceutical ingredient, while FIRMAGON® is a branded product containing degarelix.
UK medicines information currently lists both FIRMAGON 80mg Injection and Degarelix Ferring 80mg Powder and solvent for solution for injection under degarelix acetate products. Therefore, product-specific regulatory and manufacturer information should be checked before describing an individual degarelix product as a generic equivalent of Firmagon.
The UK 80mg product is supplied as a powder and solvent for solution for injection. The cited UK formulation contains 80mg degarelix per vial; after reconstitution, the solution contains 20mg of degarelix per mL. The solvent is water for injections and the powder contains mannitol.
UK pack information includes a vial, pre-filled solvent syringe, plunger rod, vial adapter and injection needle. One-tray and three-tray presentations are listed, although not every pack size may be marketed.
Degarelix should be prescribed and administered under appropriate medical supervision.
Common and very common adverse reactions include hot flushes, injection-site reactions, weight increase, dizziness, headache, fatigue, gastrointestinal symptoms and changes in liver transaminases. Injection-site reactions can include pain, erythema, swelling, induration and nodules.
Long-term androgen-deprivation therapy can affect cardiovascular and metabolic health and may be associated with prolongation of the QT interval. Patients with cardiovascular risk factors or medicines that can prolong QT should be assessed appropriately by their healthcare professional.
The UK SmPC also advises caution in patients with severe renal or hepatic impairment and notes that testosterone suppression can affect bone density and glucose tolerance over time.
Degarelix 80mg is a prescription cancer medicine with country-specific regulatory and supply requirements. UK eMC currently contains active product information for FIRMAGON 80mg and Degarelix Ferring 80mg. Australia also lists degarelix 80mg injection under the Pharmaceutical Benefits Scheme, with Firmagon 80mg identified as an available brand.
Availability, pricing, prescription requirements and permitted supply channels differ between the UK, Australia, Thailand, Russia, UAE/Dubai, South Korea and USA. Buyers should verify the regulatory status and dispensing requirements applicable to their country.
What is Degarelix 80mg Injection?
Degarelix 80mg Injection is a GnRH receptor antagonist used as androgen-deprivation therapy for hormone-dependent prostate cancer.
What is Degarelix 80mg used for?
It is used in the treatment of hormone-dependent prostate cancer, including advanced disease and certain high-risk localised or locally advanced cases where androgen-deprivation therapy is indicated.
Is Degarelix the same as Firmagon?
Firmagon is a branded medicine containing degarelix. Degarelix is the active ingredient. UK medicines information also lists Degarelix Ferring as a product containing degarelix acetate.
Is Degarelix a GnRH antagonist?
Yes. Degarelix directly blocks the GnRH receptor and suppresses testosterone production.
Is Degarelix 80mg a prescription medicine in the UK?
Yes. The UK eMC classifies the medicine as a prescription-only medicine.
What is the difference between Degarelix and GnRH agonists?
Degarelix is a GnRH antagonist and does not produce the initial testosterone surge associated with GnRH agonist therapy.
What are common Degarelix side effects?
Common reactions include injection-site reactions, hot flushes, weight increase, fatigue, dizziness, headache and changes in liver enzymes.
Is Degarelix 80mg available in Australia?
The Australian PBS currently lists degarelix 80mg injection, with Firmagon 80mg identified as an available brand.
Is Degarelix 80mg available internationally?
Product registration and supply differ by country. The medicine has documented product availability in multiple markets, but local prescription and dispensing requirements should always be checked.
Last Updated: September 19, 2026 | Medically Reviewed By: Licensed Pharmacist
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis or treatment. Degarelix is a prescription anticancer medicine and should be used only under the supervision of a qualified healthcare professional.
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.